Invitae

Invitae Net Debt per Share

Delisted

The Net Debt per Share of Invitae (NVTAQ) as of Oct 5, 2026 is 3.68 USD. In the previous year, Net Debt per Share was 1.89 USD — a change of 94.62% (higher).

Net Debt per Share

3.68USD

YoY

94.62%

Last updated:

Net Debt per Share of Invitae is 2026 3.68 USD. Net Debt per Share of Invitae was 2025 1.89 USD. It decreases by 94.62% higher compared to the previous year.

The Invitae Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2015
-0.41 USD
Jan 1, 2016
-0.28 USD
Jan 1, 2017
-0.07 USD
Jan 1, 2018
-0.17 USD
Jan 1, 2019
-0.42 USD
Jan 1, 2020
0.14 USD
Jan 1, 2021
1.89 USD
Jan 1, 2022
3.68 USD
The Invitae Net Debt per Share history
YEARNet Debt per ShareYoY
3.68USD+94.62%
1.89USD+1,289.11%
0.14USD-132.51%
-0.42USD+149.61%
-0.17USD+138.52%
-0.07USD-74.46%
-0.28USD-32.44%
-0.41USD+12.84%
-0.36USD—
Access this data via the Eulerpool API

Invitae Stock analysis

What does Invitae do? Invitae Corp is a US-based company specialized in providing genetic tests for the diagnosis, treatment, and prevention of diseases. It was founded in 2010 and is headquartered in San Francisco, California. The company's goal is to lower the cost of genetic testing and increase accessibility for patients through automation and sample pooling methods. Invitae has received significant funding and has expanded its capital through multiple rounds of investments from venture capital firms, totaling nearly half a billion dollars. Its business model focuses on offering genetic tests to a wide range of patient groups, streamlining the testing processes through automation and software optimization. Invitae serves consumers directly, as well as medical professionals, hospitals, health centers, laboratories, and health insurance companies. The company aims to improve disease diagnosis and early detection while promoting long-term patient health. Invitae has broadened its capabilities through strategic acquisitions and partnerships, consolidating genetic data on a single platform. It offers a diverse portfolio of genetic tests for the diagnosis, treatment, and prevention of various diseases, including cancer predisposition, cardiovascular diseases, rare inherited diseases, neurological disorders, and medical genomics. The company also provides genetic counseling and family-oriented diagnosis services, along with an online platform facilitating interactive communication between doctors and patients, enabling the sharing and presentation of genetic information and test results. Invitae is an innovative company that has established itself as a market leader in genetic testing, offering a wide range of products and services facilitated by advanced technologies and data storage solutions. The recent acquisitions and partnerships have expanded Invitae's portfolio, improved its technology platform, and strengthened its position as a provider of high-quality healthcare services, enabling well-informed decision-making for patients and medical professionals. Invitae is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invitae stock

Net Debt per Share of Invitae is 3.68 USD in 2026.

Net Debt per Share of Invitae changed from 1.89 USD to 3.68 USD, representing a 94.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share Invitae since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

Other — Invitae

All Key Metrics — Invitae